Fontaine progeroid syndrome (FPS) is an extremely rare genetic disorder caused by mutations in the SLC25A24 gene, which encodes a protein responsible for transporting energy-related molecules across the inner membrane of mitochondria. Children born with FPS show signs of premature aging, skull bone abnormalities, growth restriction that begins before birth, and distinctive facial features. The condition was only genetically characterized in 2017, and fewer than two dozen confirmed cases appear in the medical literature, making it one of the least-studied progeroid (premature-aging) conditions known.
What Causes Fontaine Progeroid Syndrome
FPS arises from a single-letter change in the DNA of the SLC25A24 gene. The mutation strikes at one specific spot: codon 217, which normally codes for the amino acid arginine. Two substitutions have been identified. One swaps arginine for histidine, the other swaps it for cysteine. Both are de novo mutations, meaning they are not inherited from either parent but instead arise spontaneously in the affected child.1PubMed Central. De Novo Mutations in SLC25A24 Cause a Disorder Characterized by Early Aging, Bone Dysplasia, Characteristic Face, and Early Demise Only one copy of the gene needs to carry the mutation for the syndrome to develop, and both boys and girls are affected equally.2American Journal of Human Genetics. Mutations in SLC25A24 Are Responsible for Fontaine Progeroid Syndrome
The initial genetic discovery came from exome sequencing of unrelated affected children and their parents. In each case, neither parent carried the mutation, confirming the de novo origin. A case report of a Korean girl with FPS further reinforced this pattern: family screening showed neither parent had the variant.3PubMed Central. A 9-year-old Korean girl with Fontaine progeroid syndrome: a case report with further phenotypical delineation and description of clinical course during long-term follow-up However, more recent work has detected parental mosaicism, a situation where one parent carries the mutation in a small fraction of their cells without showing symptoms, raising the theoretical possibility that in some families the recurrence risk may not be zero.4PubMed. Prenatal diagnosis of SLC25A24 Fontaine progeroid syndrome: description of the fetal phenotype, genotype and detection of parental mosaicism
How the Mutation Damages Mitochondria
SLC25A24 produces a calcium-binding mitochondrial carrier protein sometimes called SCaMC-1. Under normal conditions, this protein helps regulate the pool of adenine nucleotides, including ATP, inside the mitochondrion and plays a role in the cell’s response to oxidative stress. The mutations at codon 217 do not simply knock the protein out. Instead, they appear to create a gain of abnormal function that actively disrupts mitochondrial behavior.5PubMed Central. De Novo Mutations in SLC25A24 Cause a Craniosynostosis Syndrome with Hypertrichosis, Progeroid Appearance, and Mitochondrial Dysfunction
Laboratory studies on skin cells (fibroblasts) taken from affected children reveal several problems. Under resting conditions, the mitochondria already contain less ATP than normal, and they show visible swelling. When these cells are exposed to hydrogen peroxide, a common source of oxidative stress, the swelling gets dramatically worse and the mitochondrial membrane potential rises abnormally.6PubMed Central. De Novo Mutations in SLC25A24 Cause a Craniosynostosis Syndrome with Hypertrichosis, Progeroid Appearance, and Mitochondrial Dysfunction In parallel experiments, cells carrying the mutant gene showed a lower rate of oxygen consumption linked to ATP production, which points to impaired energy generation.7American Journal of Human Genetics. Mutations in SLC25A24 Are the Cause of Fontaine Progeroid Syndrome
The leading explanation for why this matters centers on the mitochondrial permeability transition pore, a channel that forms in stressed mitochondria and, when opened too readily, triggers cell death. Normally, SLC25A24 helps keep this pore in check by regulating calcium buffering and adenine nucleotide levels. With the mutant protein, the pore seems to form more easily, making cells more vulnerable to dying under stress.8American Journal of Human Genetics. Recurrent De Novo Mutations in SLC25A24 in Gorlin-Chaudhry-Moss Syndrome This heightened sensitivity to oxidative damage provides a plausible connection between a defective mitochondrial transporter and the premature-aging features seen in FPS patients.
Why the Protein’s Structure Matters
Molecular modeling based on the closely related bovine mitochondrial ADP/ATP carrier has shown why arginine at position 217 is so critical. In the normal protein, that single arginine holds helices 2 and 3 together through four strong hydrogen bonds with three neighboring backbone residues. The cysteine substitution abolishes all four hydrogen bonds, while the histidine substitution allows at most one to survive. Either change distorts the protein’s shape enough to narrow the internal cavity where molecules would normally pass through, fundamentally disrupting transport.9American Journal of Human Genetics. Mutations in SLC25A24 Are Associated with Fontaine Progeroid Syndrome This explains why the two known mutations both produce a similar clinical picture despite being chemically different substitutions: both sabotage the same structural linchpin.
Clinical Features at Birth and Beyond
FPS typically declares itself before birth. Prenatal ultrasound may reveal growth restriction, shortened limbs, and skull abnormalities. After delivery, the combination of features is striking enough to raise suspicion of a progeroid condition even in infancy. The syndrome spans multiple organ systems, and the constellation of findings is what often prompts genetic testing.
The hallmark features include:
- Craniosynostosis: premature fusion of skull sutures, often involving multiple or all sutures (pansynostosis), which distorts skull shape and can raise pressure on the brain.
- Facial features: midfacial retrusion (the central face appears flattened), small eyes, and a distinctive overall appearance.
- Growth restriction: both prenatal and postnatal, resulting in short stature and low weight that typically persist throughout life.
- Skin changes: generalized loose skin, decreased fat beneath the skin, and wrinkling on the forehead and limbs, even in infancy.
- Hypertrichosis: excessive hair growth, sometimes more prominent on the face and body.
- Hand and foot anomalies: shortened end bones of the fingers, small nails, and other digit abnormalities.
- Other findings: umbilical hernia, genital malformations, and wide-open fontanelles despite the craniosynostosis occurring elsewhere in the skull.
These features were formally enumerated in early case descriptions and have since been refined as more patients are identified.10PubMed. Prenatal diagnosis of SLC25A24 Fontaine progeroid syndrome: description of the fetal phenotype, genotype and detection of parental mosaicism
Craniosynostosis and Surgical Management
The skull involvement in FPS is often severe. One documented case presented at birth with not only midfacial retrusion and fusion of all major sutures but also significant absence of bone formation at the top of the skull.11FACE. Syndromic Craniosynostosis in a Child With Fontaine Progeroid Syndrome: A Rare Genetic Disorder and the Surgical Management That paradox, some sutures fusing too early while other areas of the skull fail to form bone at all, is characteristic of FPS and complicates surgical planning.
Craniosynostosis surgery in these children aims to relieve intracranial pressure and allow the brain adequate room to grow. The procedures are broadly similar to those used in other craniosynostosis syndromes, such as Crouzon or Apert syndrome, but FPS patients present unique challenges. The coexistence of bone agenesis with premature fusion means surgeons must address two opposite problems in the same skull. Poor wound healing, a downstream consequence of the connective-tissue abnormalities in FPS, adds another layer of surgical risk. Because so few cases exist, no standardized surgical protocol has emerged, and management decisions are made case by case.
The Overlap with Gorlin-Chaudry-Moss Syndrome
For years, Gorlin-Chaudry-Moss syndrome (GCMS) and Fontaine-Farriaux syndrome were considered separate conditions. GCMS was described in 1960 and featured craniosynostosis, hypertrichosis, small eyes, and other abnormalities that, in retrospect, look remarkably like what was later called Fontaine-Farriaux syndrome. The 2017 genetic discoveries revealed that both conditions are caused by the same SLC25A24 mutations at codon 217.12PubMed Central. De Novo Mutations in SLC25A24 Cause a Craniosynostosis Syndrome with Hypertrichosis, Progeroid Appearance, and Mitochondrial Dysfunction What had been treated as two rare syndromes turned out to be one disorder with some variability in presentation. FPS is now the umbrella term, though you may still encounter older references using the GCMS label.
This unification matters for families and clinicians because it effectively doubles the pool of known cases, small as it still is. It also means that findings from GCMS research apply directly to FPS patients, and vice versa, consolidating what would otherwise be two separate and even thinner literatures into one.
Distinguishing FPS from Other Progeroid Conditions
The premature-aging appearance in a newborn triggers a differential diagnosis that includes several other rare conditions. The most widely known progeroid syndrome, Hutchinson-Gilford progeria, does not overlap much in practice because its features typically become apparent only around age one and a half to two years, well after the FPS phenotype is already obvious at birth. Other conditions that enter the differential include Wiedemann-Rautenstrauch syndrome (also called neonatal progeroid syndrome), which shares the loose, wrinkled skin and fat loss but involves different genetic pathways, and Cockayne syndrome, which features growth failure and photosensitivity but a different facial appearance. Marfan-progeroid lipodystrophy and Seckel syndrome may also need to be considered.
In practice, the combination of craniosynostosis with a progeroid appearance narrows the field considerably, because most neonatal progeroid syndromes do not involve premature skull fusion. Genetic testing of the SLC25A24 gene provides a definitive answer and can now be done prenatally when there is reason for suspicion.13PubMed. Prenatal diagnosis of SLC25A24 Fontaine progeroid syndrome: description of the fetal phenotype, genotype and detection of parental mosaicism
How Long Do Children with FPS Live
Early reports painted a grim picture, with several patients dying in infancy or early childhood. The initial 2017 genetic studies included individuals who did not survive past their first years. However, subsequent case reports have expanded the known range of outcomes. A 9-year-old Korean girl was described with long-term follow-up showing a nearly normal developmental outcome despite her physical features.14PubMed Central. A 9-year-old Korean girl with Fontaine progeroid syndrome: a case report with further phenotypical delineation and description of clinical course during long-term follow-up A Spanish boy with a confirmed mutation was reported alive at 15 years old with normal cognitive and motor development, making him the first male patient documented to survive at least into adolescence.15PubMed. A rare male patient with Fontaine progeroid syndrome caused by p.R217H de novo mutation in SLC25A24
These longer-surviving patients share an important detail: their intellectual development appears largely preserved. The brain itself does not seem to be a primary target of the disease in the way that bone, skin, and connective tissue are. That said, secondary neurological complications from untreated craniosynostosis, such as raised intracranial pressure, could threaten cognitive outcomes if not addressed surgically. It remains unclear whether differences in which specific mutation a patient carries (histidine versus cysteine) influence prognosis, because the number of known cases is too small to draw firm comparisons.
What Day-to-Day Management Looks Like
There is no treatment that addresses the underlying mitochondrial defect in FPS. Management is entirely supportive and typically involves a team of specialists. Craniofacial surgeons address the skull abnormalities, often in staged procedures during the first years of life. Ophthalmologists monitor the small eyes and any associated vision problems. Dermatologists may be consulted for the skin changes, and endocrinologists often track growth. Nutritional support is frequently needed given the severe growth restriction and reduced body fat.
Because the connective tissue is broadly affected, wound healing after surgery can be slow, and surgical teams need to plan accordingly. The umbilical hernias seen in some patients may require repair. The digit and nail abnormalities are mostly cosmetic concerns, though shortened fingers can affect fine motor skills in older children. For families, the rarity of the condition means that finding clinicians with direct experience is nearly impossible. Most care is coordinated through academic medical centers with genetics departments.
The Burden on Families
Caring for a child with an ultra-rare disease like FPS imposes burdens that go well beyond the medical. Research on caregivers of children with ultra-rare diseases has found that close to half report feeling overloaded by their caregiving responsibilities, and a similar proportion report coping poorly with the associated stress.16PubMed. Ultra-rare ultra-care: Assessing the impact of caring for children with ultra rare diseases Many experience emotional distress tied specifically to the unpredictability of the condition and the absence of established treatment guidelines.
For FPS families in particular, the diagnostic odyssey can be prolonged. Because the condition is so rare, many physicians have never encountered it, and genetic testing may not be ordered immediately. Parents frequently describe months or years of consultations before a definitive answer. Even after diagnosis, the scarcity of published case reports means that clinicians have limited evidence to guide families about what to expect. Online communities for ultra-rare genetic conditions have become a lifeline for some families, connecting them with the handful of other families worldwide who share the same diagnosis.
Open Questions in FPS Research
The science of FPS is still in its earliest stages. The gene was identified only in 2017, and most published work consists of individual case reports and cell-based laboratory experiments. No animal model faithfully recapitulating the human disease has been described in the literature, which limits the ability to test potential interventions. The fibroblast studies have been valuable for understanding the mitochondrial defect, but skin cells are a rough proxy for the developing skull, skeleton, and fat tissue that are most affected clinically.
One area of genuine scientific interest is the connection between SLC25A24 and cancer. In healthy cells, the protein is known to be overexpressed in many tumors and highly proliferative cell lines, where it appears to protect cells from dying under stress.17American Journal of Human Genetics. Mutations in SLC25A24 Are the Cause of Fontaine Progeroid Syndrome Knocking the protein down in cancer cell experiments makes those cells more susceptible to death from oxidative stress and calcium overload. The FPS mutations, by contrast, seem to create a version of the protein that makes cells more fragile rather than more resilient. Whether FPS patients have an altered cancer risk, higher or lower, is unknown, but the biology raises the question. This dual role of SLC25A24 as a pro-survival factor in cancer and a source of cell fragility when mutated is one of the more intriguing puzzles the condition has opened up for basic science.
The discovery of parental mosaicism has also reshaped genetic counseling for FPS. Until recently, families were told the recurrence risk was essentially negligible because every confirmed case was de novo. The identification of low-level mosaicism in at least one parent now means that prenatal testing should be offered in subsequent pregnancies for families with an affected child, and the conversation about recurrence risk has become more nuanced than a simple reassurance.